Aspirin in the treatment of acute migraine attacks

Expert Review of Neurotherapeutics

Volumn 6, Issue 4, 2006, Pages 563-573

  Diener, Hans Christoph ^a   Lampl, Christian ^b   Reimnitz, Peter ^c   Voelker, Michael ^d  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c BAYER AG   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

Aspirin; Headache; Metoclopramide; Migraine; Sumatriptan; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIEMETIC AGENT; CAFFEINE; CODEINE; ERGOTAMINE; METOCLOPRAMIDE; PARACETAMOL; SUMATRIPTAN;

ACUTE DISEASE; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EFFERVESCENT TABLET; HEADACHE; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; META ANALYSIS; MIGRAINE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ASPIRIN; HUMANS; MIGRAINE DISORDERS; PAIN MEASUREMENT;

EID: 33646807777     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.4.563     Document Type: Review

References (45)

1. Silberstein SD. Migraine. Lancet 363, 381-391 (2004).
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159, 813-818 (1999).
3. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can. J. Neurol. Sci. 20, 131-137 (1993).
4. Adelman JU, Von Seggern RL, Mannix LK. Migraine headaches: implications for management from a nationwide patient survey. Headaches 11, 105-112 (1999).
5. Vane JR, Botting RM (Eds). Aspirin and Other Salicylates. Chapman & Hall Medical, London, UK (1992).
6. Rainsford KD (Ed). Aspirin and Related Drugs. Taylor & Francis, London, UK (2004).
7. Martindale R. The Extra Pharmacopoeia. 31st Edition. London Royal Pharmaceutical Society, UK (1996).
8. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 24, 1601-1610 (2003).
9. Patrono C, Bachmann F, Baigent C et al. Expert concensus document on the use of antiplatelet agents. Eur. Heart J. 25, 166-181 (2004).
10. Kune G. Colorectal cancer chemoprevention with aspirin. Gastrointest. Oncol. 4, 5-15 (2002).
11. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003).
12. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890 (2003).
13. Vane JR. Inhibition of prostaglandin synthesis as a mechansim of action of aspirin-like drugs. Nature 231, 232-235 (1971). •• Explains the mode of action of aspirin in pain. Resulted in the Nobel prize.
14. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 231, 235-237 (1971).
15. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol. Ther. 49, 153-179 (1991).
16. Smith WL. Molecular mechanism of aspirin action. Drug News Persp. 4, 362-366 (1991).
17. Shimokawa T, Smith WL. Prostaglandin endoperoxidase synthase - the aspirin acetylation region. J. Biol. Chem. 267, 12387-12392 (1992).
18. Vane J. Towards a better aspirin. Nature 367, 215-216 (1994).
19. Allen KN. Aspirin - now we can see it. Knowing how aspirin interacts with its targets make it all better. Nature Med. 1, 882-883 (1995).
20. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol. Sci. 20, 4-6 (1999).
21. Fitzgerald GA. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
22. Buzzi M, Sakas D, Moskowitz M. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur. J. Pharmacol. 165, 251-258 (1989).
23. Kaube, Hoskin K, Goadsby P. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33, 541-544 (1993).
24. Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J. Pharm. Sci. 61, 379-385 (1972).
25. Pedersen AK, Fitzgerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311, 1206-1211 (1984).
26. Shen J, Wanwimolruk S, Purves RD, McQueen EG, Roberts MS. Model representation of salicylate pharmacokinetcis using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose. J. Pharmcokinet. Biopharm.19, 575-595 (1991).
27. Tfelt-Hansen P, Olesen J. Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. Eur. Neurol. 19, 163-165 (1980).
28. Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 14, 156-161 (1994).
29. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache 45, 283-292 (2005).
30. MacGregor EA, Dowson A, Davies PTG. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42, 249-255 (2002).
31. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur. Neurol. 32, 177-184 (1992). •• First major study to compare a triptan with aspirin plus metoclopramide.
32. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 14, 297-300 (1994).
33. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346, 923-926 (1995).
34. Geraud G, Compagnon A, Rossi A; COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur. Neurol. 47, 88-98 (2002).
35. Titus F, Escamilla C, da Costa Palmeira MMG, Leira R, Monteiro JMP. A double-blind comparison of lysine acetylsalicylate plus metoclopramide vs ergotamine plus caffeine in migraine. Clin. Drug Invest. 21, 87-94 (2001).
36. Taneri Z, Petersen-Braun M. Therapie des akuten migräneanfalls mit intravenös applizierter acetylsalicylsäre. Eine plazebokontrollierte doppelblindstudie. Der. Schmerz. 9, 124-129 (1985).
37. Limmroth V, May A, Diener HC. Lysine-acetylsalicylic acid in acute migraine attacks. Eur. Neurol. 41, 88-93 (1999).
38. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 19, 581-588 (1999).
39. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 4, 107-111 (1984).
40. Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 20, 663-667 (2000).
41. Diener HC, Bussone G, de Liano H et al; EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24, 947-954 (2004).
42. Diener HC, Eikermann A, Gessner U et al. Efficacy of 1000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur. Neurol. 52, 50-56 (2004).
43. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine (first edition). Cephalalgia 11, 1-12 (1991).
44. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine (second edition). Cephalalgia 20, 765-786 (2000).
45. Fries JF. The epidemiology of NSAID gastropathy. The ARAMIS experience. J. Clin. Rheumatol. 4, S11-S16 (1998).